{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T10:31:48Z","timestamp":1783593108910,"version":"3.55.0"},"reference-count":44,"publisher":"American Society of Hematology","issue":"5","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,8,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This phase 1\/2 study assessed the safety, tolerability, and preliminary efficacy of the oral proteasome inhibitor (PI) ixazomib in patients with relapsed\/refractory immunoglobulin light chain (AL) amyloidosis. Ixazomib was administered to adult patients with relapsed\/refractory AL amyloidosis after 1 or more prior lines of therapy (including bortezomib) on days 1, 8, and 15 of 28-day cycles, for up to 12 cycles. Patients with less than partial response after 3 cycles received oral dexamethasone (40 mg, days 1-4) from cycle 4. A 3+3 dose-escalation phase was followed by 2 expansion cohorts (PI-naive and PI-exposed patients) at the maximum tolerated dose (MTD). Twenty-seven patients were enrolled: 11 during dose escalation (6 at 4.0 mg and 5 at 5.5 mg) and 16 during dose expansion (4.0 mg). Three patients experienced dose-limiting toxicities: 1 at 4.0 mg and 2 at 5.5 mg; the MTD was determined as 4.0 mg. Most common adverse events (AEs) included nausea, skin and subcutaneous tissue disorders (SSTD), diarrhea, and fatigue; grade 3 or higher AEs included dyspnea, fatigue, and SSTD. Overall, the hematologic response rate was 52% in patients treated at the MTD (n = 21). Organ responses were seen in 56% of patients (5 cardiac, 5 renal). Median hematologic progression-free survival was 14.8 months; 1-year progression-free and overall survival rates were 60% and 85%, respectively (median follow-up, 16.9 months). Weekly oral ixazomib appears to be active in patients with relapsed\/refractory AL amyloidosis, with a generally manageable safety profile. The study was registered at clinicaltrials.gov as #NCT01318902. A phase 3 study is ongoing (#NCT01659658).<\/jats:p>","DOI":"10.1182\/blood-2017-03-771220","type":"journal-article","created":{"date-parts":[[2017,5,26]],"date-time":"2017-05-26T20:50:16Z","timestamp":1495831816000},"page":"597-605","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":105,"title":["A phase 1\/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis"],"prefix":"10.1182","volume":"130","author":[{"given":"Vaishali","family":"Sanchorawala","sequence":"first","affiliation":[{"name":"Amyloidosis Center, Boston University School of Medicine, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Palladini","sequence":"first","affiliation":[{"name":"Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy;"},{"name":"Department of Molecular Medicine, University of Pavia, Pavia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Kukreti","sequence":"first","affiliation":[{"name":"Princess Margaret Hospital, Toronto, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Zonder","sequence":"first","affiliation":[{"name":"Barbara Ann Karmanos Cancer Institute, Detroit, MI;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam D.","family":"Cohen","sequence":"first","affiliation":[{"name":"Fox Chase Cancer Center, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Seldin","sequence":"first","affiliation":[{"name":"Amyloidosis Center, Boston University School of Medicine, Boston, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Dispenzieri","sequence":"first","affiliation":[{"name":"Mayo Clinic, Rochester, MN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Jaccard","sequence":"first","affiliation":[{"name":"Centre Hospitalier Universitaire, Limoges, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan O.","family":"Sch\u00f6nland","sequence":"first","affiliation":[{"name":"Medical Department V, Amyloidosis Center, University Hospital of Heidelberg, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Berg","sequence":"first","affiliation":[{"name":"Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huyuan","family":"Yang","sequence":"first","affiliation":[{"name":"Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Gupta","sequence":"first","affiliation":[{"name":"Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ai-Min","family":"Hui","sequence":"first","affiliation":[{"name":"Millennium Pharmaceuticals Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond L.","family":"Comenzo","sequence":"first","affiliation":[{"name":"Tufts Medical Center, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Merlini","sequence":"first","affiliation":[{"name":"Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy;"},{"name":"Department of Molecular Medicine, University of Pavia, Pavia, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"2","key":"2020022509293803200_B1","doi-asserted-by":"crossref","first-page":"179","DOI":"10.6004\/jnccn.2007.0018","article-title":"Managing systemic light-chain amyloidosis","volume":"5","author":"Comenzo","year":"2007","journal-title":"J Natl Compr Canc Netw"},{"issue":"14","key":"2020022509293803200_B2","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1200\/JCO.2010.32.2271","article-title":"Amyloidosis: pathogenesis and new therapeutic options","volume":"29","author":"Merlini","year":"2011","journal-title":"J Clin Oncol"},{"issue":"26","key":"2020022509293803200_B3","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1182\/blood-2013-01-453001","article-title":"Systemic light chain amyloidosis: an update for treating physicians","volume":"121","author":"Merlini","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2020022509293803200_B4","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1586\/17474086.2014.858594","article-title":"Immunoglobulin light chain amyloidosis","volume":"7","author":"Merlini","year":"2014","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"2020022509293803200_B5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1182\/blood-2016-01-629790","article-title":"What is new in diagnosis and management of light chain amyloidosis?","volume":"128","author":"Palladini","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2020022509293803200_B6","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3324\/haematol.2013.095463","article-title":"Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach","volume":"99","author":"Palladini","year":"2014","journal-title":"Haematologica"},{"issue":"2","key":"2020022509293803200_B7","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1182\/blood-2006-07-032987","article-title":"The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis","volume":"109","author":"Dispenzieri","year":"2007","journal-title":"Blood"},{"issue":"15","key":"2020022509293803200_B8","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/blood-2016-12-756528","article-title":"A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis","volume":"129","author":"Palladini","year":"2017","journal-title":"Blood"},{"issue":"16","key":"2020022509293803200_B9","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1182\/blood-2014-04-568329","article-title":"Long-term follow-up from a phase 1\/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis","volume":"124","author":"Reece","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2020022509293803200_B10","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood-2011-02-334227","article-title":"Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1\/2 study","volume":"118","author":"Reece","year":"2011","journal-title":"Blood"},{"issue":"8","key":"2020022509293803200_B11","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1182\/blood-2016-04-710822","article-title":"Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial","volume":"128","author":"Sanchorawala","year":"2016","journal-title":"Blood"},{"issue":"2","key":"2020022509293803200_B12","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood-2006-07-030544","article-title":"Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial","volume":"109","author":"Sanchorawala","year":"2007","journal-title":"Blood"},{"issue":"3","key":"2020022509293803200_B13","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/ajh.23898","article-title":"Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis","volume":"90","author":"Kaufman","year":"2015","journal-title":"Am J Hematol"},{"issue":"10","key":"2020022509293803200_B14","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.3324\/haematol.11413","article-title":"Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response","volume":"92","author":"Gertz","year":"2007","journal-title":"Haematologica"},{"issue":"2","key":"2020022509293803200_B15","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1182\/blood-2007-02-076034","article-title":"Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis","volume":"110","author":"Palladini","year":"2007","journal-title":"Blood"},{"issue":"4","key":"2020022509293803200_B16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","article-title":"Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004","volume":"79","author":"Gertz","year":"2005","journal-title":"Am J Hematol"},{"issue":"36","key":"2020022509293803200_B17","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","article-title":"New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes","volume":"30","author":"Palladini","year":"2012","journal-title":"J Clin Oncol"},{"issue":"4","key":"2020022509293803200_B18","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.bbmt.2015.12.021","article-title":"New light chain amyloid response criteria help risk stratification of patients by day 100 after autologous hematopoietic cell transplantation","volume":"22","author":"D\u2019Souza","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"21","key":"2020022509293803200_B19","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1200\/JCO.2013.48.7736","article-title":"New hematologic response criteria predict survival in patients with immunoglobulin light chain amyloidosis treated with high-dose melphalan and autologous stem-cell transplantation","volume":"31","author":"Girnius","year":"2013","journal-title":"J Clin Oncol"},{"issue":"5","key":"2020022509293803200_B20","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood"},{"issue":"4","key":"2020022509293803200_B21","doi-asserted-by":"crossref","first-page":"E60","DOI":"10.1002\/ajh.23936","article-title":"Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies","volume":"90","author":"Kastritis","year":"2015","journal-title":"Am J Hematol"},{"issue":"2","key":"2020022509293803200_B22","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3324\/haematol.2013.087619","article-title":"Update on treatment of light chain amyloidosis","volume":"99","author":"Mahmood","year":"2014","journal-title":"Haematologica"},{"key":"2020022509293803200_B23","first-page":"287","article-title":"Systemic light-chain amyloidosis: advances in diagnosis, prognosis, and therapy","volume-title":"Hematology Am Soc Hematol Educ Program","author":"Cohen","year":"2010"},{"issue":"10","key":"2020022509293803200_B24","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.3324\/haematol.2013.094482","article-title":"Light chain amyloidosis: the heart of the problem","volume":"98","author":"Merlini","year":"2013","journal-title":"Haematologica"},{"issue":"1","key":"2020022509293803200_B25","first-page":"45","article-title":"Primary systemic amyloidosis: clinical and laboratory features in 474 cases","volume":"32","author":"Kyle","year":"1995","journal-title":"Semin Hematol"},{"issue":"19","key":"2020022509293803200_B26","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","article-title":"Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis","volume":"119","author":"Mikhael","year":"2012","journal-title":"Blood"},{"key":"2020022509293803200_B27","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1038\/bcj.2014.93","article-title":"Cardiac complications in relapsed and refractory multiple myeloma patients treated with carfilzomib","volume":"5","author":"Atrash","year":"2015","journal-title":"Blood Cancer J"},{"issue":"Suppl 3","key":"2020022509293803200_B28","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/j.clml.2015.07.199","article-title":"Safety and efficacy of carfilzomib (CFZ) in previously-treated systemic light-chain (AL) amyloidosis","volume":"15","author":"Cohen","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"7","key":"2020022509293803200_B29","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1182\/blood-2014-01-548941","article-title":"Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed\/refractory multiple myeloma","volume":"124","author":"Kumar","year":"2014","journal-title":"Blood"},{"issue":"13","key":"2020022509293803200_B30","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S1470-2045(14)71125-8","article-title":"Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1\/2 study","volume":"15","author":"Kumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"17","key":"2020022509293803200_B31","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"2020022509293803200_B32","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood-2014-01-548826","article-title":"Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed\/refractory multiple myeloma patients","volume":"124","author":"Richardson","year":"2014","journal-title":"Blood"},{"key":"2020022509293803200_B33","article-title":"Osaka, Japan: Takeda Pharmaceuticals Limited","author":"Ninlaro (ixazomib) capsules, for oral use [package insert]","year":"2015"},{"issue":"10","key":"2020022509293803200_B34","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/jcph.719","article-title":"The effect of a high-fat meal on the pharmacokinetics of ixazomib, an oral proteasome inhibitor, in patients with advanced solid tumors or lymphoma","volume":"56","author":"Gupta","year":"2016","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"2020022509293803200_B35","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/bcp.12991","article-title":"Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment","volume":"82","author":"Gupta","year":"2016","journal-title":"Br J Clin Pharmacol"},{"issue":"15","key":"2020022509293803200_B36","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"issue":"5","key":"2020022509293803200_B37","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1007\/s11136-014-0853-y","article-title":"Identifying changes in scores on the EORTC-QLQ-C30 representing a change in patients\u2019 supportive care needs","volume":"24","author":"Snyder","year":"2015","journal-title":"Qual Life Res"},{"key":"2020022509293803200_B38","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13045-015-0198-1","article-title":"Pharmacokinetics and safety of ixazomib plus lenalidomide-dexamethasone in Asian patients with relapsed\/refractory myeloma: a phase 1 study","volume":"8","author":"Gupta","year":"2015","journal-title":"J Hematol Oncol"},{"key":"2020022509293803200_B39","article-title":"Population pharmacokinetic analysis of ixazomib, an oral proteasome inhibitor, including data from the phase III TOURMALINE-MM1 study to inform labelling [published online ahead of print 13 March 2017]","author":"Gupta","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"2020022509293803200_B40","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1158\/0008-5472.CAN-09-2766","article-title":"Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer","volume":"70","author":"Kupperman","year":"2010","journal-title":"Cancer Res"},{"issue":"5","key":"2020022509293803200_B41","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/clinchem\/46.5.673","article-title":"Proteasome inhibition measurements: clinical application","volume":"46","author":"Lightcap","year":"2000","journal-title":"Clin Chem"},{"issue":"5","key":"2020022509293803200_B42","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1258\/ebm.2011.010394","article-title":"Functional 20S proteasomes in mature human red blood cells","volume":"236","author":"Neelam","year":"2011","journal-title":"Exp Biol Med (Maywood)"},{"issue":"24","key":"2020022509293803200_B43","doi-asserted-by":"crossref","first-page":"5126","DOI":"10.1182\/blood-2010-06-290668","article-title":"Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features","volume":"116","author":"Kumar","year":"2010","journal-title":"Blood"},{"issue":"9","key":"2020022509293803200_B44","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","article-title":"Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements","volume":"30","author":"Kumar","year":"2012","journal-title":"J Clin Oncol"}],"updated-by":[{"DOI":"10.1182\/blood.2020005086","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2020,3,26]],"date-time":"2020-03-26T00:00:00Z","timestamp":1585180800000}}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/5\/597\/1717433\/blood771220.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/5\/597\/1717433\/blood771220.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T09:30:03Z","timestamp":1582623003000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/130\/5\/597\/36786\/A-phase-12-study-of-the-oral-proteasome-inhibitor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,3]]},"references-count":44,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,8,3]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2017-03-771220","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727658094.793549876","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,3]]}}}